These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36436670)

  • 1. Use of budesonide associated with a pulmonary surfactant to prevent bronchopulmonary dysplasia in premature newborns - A systematic review.
    Moraes LHA; Coelho RMD; Neves Dos Santos Beozzo GP; Yoshida RAM; de Albuquerque Diniz EM; de Carvalho WB
    J Pediatr (Rio J); 2023; 99(2):105-111. PubMed ID: 36436670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratracheal Administration of Budesonide-Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis.
    Venkataraman R; Kamaluddeen M; Hasan SU; Robertson HL; Lodha A
    Pediatr Pulmonol; 2017 Jul; 52(7):968-975. PubMed ID: 28165675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial.
    Manley BJ; Kamlin COF; Donath S; Huang L; Birch P; Cheong JLY; Dargaville PA; Dawson JA; Doyle LW; Jacobs SE; Wilson R; Davis PG; McKinlay CJD
    Trials; 2023 May; 24(1):320. PubMed ID: 37161488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of combined administration of surfactant and intratracheal budesonide compared to surfactant alone on bronchopulmonary dysplasia (BPD) and mortality rate in preterm infants with respiratory distress syndrome: a single-blind randomized clinical trial.
    Marzban A; Mokhtari S; Tavakkolian P; Mansouri R; Jafari N; Maleki A
    BMC Pediatr; 2024 Apr; 24(1):262. PubMed ID: 38643076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: statistical analysis plan for the international, multicenter, randomized PLUSS trial.
    Francis KL; McKinlay CJD; Kamlin COF; Cheong JLY; Dargaville PA; Dawson JA; Doyle LW; Jacobs SE; Davis PG; Donath SM; Manley BJ
    Trials; 2023 Nov; 24(1):709. PubMed ID: 37932774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia.
    Yeh TF; Chen CM; Wu SY; Husan Z; Li TC; Hsieh WS; Tsai CH; Lin HC
    Am J Respir Crit Care Med; 2016 Jan; 193(1):86-95. PubMed ID: 26351971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Effects of Intratracheal Budesonide and Surfactant for the Prevention of Bronchopulmonary Dysplasia: A Narrative Review.
    Nobile S; Di Sipio Morgia C; Hall M
    Am J Perinatol; 2024 May; 41(S 01):e1858-e1865. PubMed ID: 37279790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of early combined utilization of budesonide and surfactant by airway for bronchopulmonary dysplasia prevention in premature infants with RDS: A meta-analysis.
    Tang W; Chen S; Shi D; Ai T; Zhang L; Huang Y; Fan Y; Du Y
    Pediatr Pulmonol; 2022 Feb; 57(2):455-469. PubMed ID: 34783192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
    Bassler D
    Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratracheal administration of budesonide with surfactant in very low birth weight infants to prevent bronchopulmonary dysplasia.
    Heo M; Jeon GW
    Turk J Pediatr; 2020; 62(4):551-559. PubMed ID: 32779407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of intratracheal administration of budesonide combined with pulmonary surfactant in preventing bronchopulmonary dysplasia: a prospective randomized controlled trial.
    Liu MM; Ji L; Dong MY; Zhu XF; Wang HJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jan; 24(1):78-84. PubMed ID: 35177180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shaken or Stirred? Evaluating the combination of budesonide-surfactant for survival free of bronchopulmonary dysplasia.
    Willis K; Weems M
    Acta Paediatr; 2018 Mar; 107(3):540. PubMed ID: 29131394
    [No Abstract]   [Full Text] [Related]  

  • 13. Animal derived surfactant extract for treatment of respiratory distress syndrome.
    Seger N; Soll R
    Cochrane Database Syst Rev; 2009 Apr; (2):CD007836. PubMed ID: 19370695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review shows that using surfactant a number of times or as a vehicle for budesonide may reduce the risk of bronchopulmonary dysplasia.
    Hascoët JM; Picaud JC; Ligi I; Blanc T; Daoud P; Zupan V; Moreau F; Guilhoto I; Rouabah M; Alexandre C; Saliba E; Storme L; Patkai J; Pomedio M; Hamon I
    Acta Paediatr; 2018 Jul; 107(7):1140-1144. PubMed ID: 29193276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis.
    Zhong YY; Li JC; Liu YL; Zhao XB; Male M; Song DK; Bai Y
    Curr Med Sci; 2019 Jun; 39(3):493-499. PubMed ID: 31209823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial.
    Dargaville PA; Kamlin COF; Orsini F; Wang X; De Paoli AG; Kanmaz Kutman HG; Cetinkaya M; Kornhauser-Cerar L; Derrick M; Özkan H; Hulzebos CV; Schmölzer GM; Aiyappan A; Lemyre B; Kuo S; Rajadurai VS; O'Shea J; Biniwale M; Ramanathan R; Kushnir A; Bader D; Thomas MR; Chakraborty M; Buksh MJ; Bhatia R; Sullivan CL; Shinwell ES; Dyson A; Barker DP; Kugelman A; Donovan TJ; Tauscher MK; Murthy V; Ali SKM; Yossuck P; Clark HW; Soll RF; Carlin JB; Davis PG;
    JAMA; 2021 Dec; 326(24):2478-2487. PubMed ID: 34902013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants.
    Soll RF; Morley CJ
    Cochrane Database Syst Rev; 2001; (2):CD000510. PubMed ID: 11405966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome.
    Bahadue FL; Soll R
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD001456. PubMed ID: 23152207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratracheal Budesonide/Surfactant for Preventing Bronchopulmonary Dysplasia.
    Dani C
    Am J Respir Crit Care Med; 2016 Jul; 194(1):123. PubMed ID: 27367894
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants.
    Singh N; Halliday HL; Stevens TP; Suresh G; Soll R; Rojas-Reyes MX
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010249. PubMed ID: 26690260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.